Jul 27, 2004

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study

Depression and Anxiety
Jonathan R T DavidsonHongjie Zheng

Abstract

Escitalopram has been shown in clinical trials to improve anxiety symptoms associated with depression, panic disorder, and social anxiety disorder. This study was designed to evaluate the efficacy and tolerability of escitalopram in the treatment of generalized anxiety disorder (GAD). Outpatients (18 years or older) who met DSM-IV criteria for GAD, with baseline Hamilton Rating Scale for Anxiety (HAMA) scores > or = 18, were randomly assigned to double blind treatment with escitalopram (10 mg/day for the first 4 weeks and then flexibly dosed from 10-20 mg/day) or placebo for 8 weeks, following a 1-week, single-blind, placebo lead-in period. The primary efficacy variable was the mean change from baseline in total HAMA score at Week 8. The escitalopram group (N = 158) showed a statistically significant, and clinically relevant, greater improvement at endpoint compared with placebo (N = 157) in all prospectively defined efficacy parameters. Significant improvement in HAMA total score and HAMA psychic anxiety subscale score for the escitalopram-treated group vs. the placebo-treated group was observed beginning at Week 1 and at each study visit thereafter. Mean changes from baseline to Week 8 on the HAMA total score using a last-obs...Continue Reading

Mentioned in this Paper

Drug Tolerance
Adverse Event
Panic Disorder 1
Measurement of Human Anti-mouse Antibody
Outpatients
Anxiety Disorders
Selective Serotonin Reuptake Inhibitors
Anxiety States, Neurotic
Clinical Trial [Publication Type]
Dose-Response Relationship, Drug

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.